Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP12 | P39900 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222057 | 1.00 | PTPN1 (0.48) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3221869 | 0.92 | PTPN1 (0.47) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3221860 | 0.92 | PTPN1 (0.47) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14395947 | 0.92 | PTPN1 (0.47) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1732454 | 0.88 | ALDH1A1 (0.43) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1732457 | 0.88 | ALDH1A1 (0.43) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1731983 | 0.84 | MMP2 (0.48) | PTPN1ALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL1731666 | 0.84 | MMP2 (0.48) | PTPN1ALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL1731486 | 0.84 | PTPN2 (0.46) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1731489 | 0.84 | PTPN2 (0.46) | PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | claimed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | JEYASEELAN JEY RAJU | 2010-02-11 | — | — | US | disclosed |
| EP-2089026-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008070552-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | NOVARTIS AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008067527-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE TREATMENT OF MUSCLE ATROPHY AND RELATED DISORDERS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885PTPN2 5/4885ALDH1A1 2621/4885 |
| US-20100035860-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE FOR THE PROMOTION OF PHYSIOLOGICAL CARDIAC HYPERTROPHY | PPM1A, TNNI3, PTPA | PTPN1 41/4885PTPN2 39/4885ALDH1A1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.